Morten Schou

Finerenone and Atrial Fibrillation in Heart Failure

The Efficacy of Finerenone on Hierarchical Composite Endpoint Analysed Using Win Statistics in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of FINEARTS-HF

Efficacy and Tolerability of Finerenone According to the Use and Dosage of Diuretics

Baseline Characteristics of Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Trial

Myeloperoxidase Inhibition in Heart Failure With Preserved or Mildly Reduced Ejection Fraction: SATELLITE Trial Results

All-cause mortality and location of death in patients with established cardiovascular disease before, during, and after the COVID-19 lockdown: a Danish Nationwide Cohort Study

Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial

Importance of diagnostic setting in determining mortality in patients with new-onset heart failure: temporal trends in Denmark from 1997 to 2017

Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: a nationwide study in <scp>Denmark</scp> from 2003–2017

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy

The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study

New-onset atrial fibrillation: incidence, characteristics, and related events following a national COVID-19 lockdown of 5.6 million people

Cardiovascular comorbidities as predictors for severe COVID-19 infection or death

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction